$BRTX
BioRestorative Therapies, Inc. Stock $brtx

$brtx Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415049960 Filed on August 14, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$96.12K	$148.8K	$175.9K
YoY Change	-39.9%	-15.45%	41297.88%
Cost Of Revenue	$50.92K	$74.65K	$42.37K
YoY Change	-22.98%	76.19%	117583.33%
Gross Profit	$45.20K	$74.12K	$133.6K
YoY Change	-51.82%	-44.51%	34238.05%
Gross Profit Margin	47.02%	49.82%	75.92%
Selling, General & Admin	$920.0K	$880.0K	$1.120M
YoY Change	31.43%	-21.43%
% of Gross Profit	2035.35%	1187.28%	838.48%
Research & Development	$615.6K	$452.5K	$293.3K
YoY Change	111.78%	54.26%	-21.34%
% of Gross Profit	1362.02%	610.49%	219.6%
Depreciation & Amortization	$60.00K	$50.00K	$20.00K
YoY Change	200.0%	150.0%
% of Gross Profit	132.74%	67.46%	14.97%
Operating Expenses	$1.535M	$1.337M	$1.415M
YoY Change	55.09%	-5.52%	26.99%
Operating Profit	-$1.490M	-$1.263M	-$1.281M
YoY Change	66.28%	-1.46%	15.05%
Interest Expense	$80.65K	$60.10K	$72.39K
YoY Change	7.85%	-16.98%	125.97%
% of Operating Profit
Other Income/Expense, Net	-$133.9K	-$157.5K	-$51.65K
YoY Change	-34.49%	204.91%	-62.38%
Pretax Income	-$1.620M	-$1.420M	-$1.330M
YoY Change	47.27%	6.77%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.624M	-$1.420M	-$1.333M
YoY Change	47.56%	6.54%	6.55%
Net Earnings / Revenue	-1689.35%	-954.73%	-757.72%
Basic Earnings Per Share
Diluted Earnings Per Share	-$572.4K	-$636.8K	-$1.167M
COMMON SHARES
Basic Shares Outstanding	2.826M shares	39.15M shares	22.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.00K	$10.00K	$60.00K
YoY Change	-97.3%	-83.33%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$370.0K	$180.0K	$20.00K
YoY Change	1133.33%	800.0%
Inventory	$2.492K	$2.492K	$20.00K
Prepaid Expenses
Receivables		$50.98K	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$385.0K	$246.1K	$100.0K
YoY Change	-8.66%	146.14%	51.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$662.5K	$702.3K	$20.00K
YoY Change	800.44%	3411.74%	-51.47%
Goodwill
YoY Change
Intangibles	$1.057M	$1.076M
YoY Change	0.22%
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K
YoY Change	0.0%
Total Long-Term Assets	$1.766M	$1.824M	$1.090M
YoY Change	50.33%	67.38%	-7.91%
TOTAL ASSETS
Total Short-Term Assets	$385.0K	$246.1K	$100.0K
Total Long-Term Assets	$1.766M	$1.824M	$1.090M
Total Assets	$2.151M	$2.071M	$1.190M
YoY Change	34.75%	74.0%	-4.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.110M	$1.747M	$890.0K
YoY Change	172.62%	96.25%	-11.27%
Accrued Expenses	$1.969M	$1.887M	$1.230M
YoY Change	61.38%	53.45%	-10.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.240M	$1.120M	$5.910M
YoY Change	-76.02%	-81.05%
Total Short-Term Liabilities	$5.465M	$4.920M	$8.260M
YoY Change	-26.42%	-40.44%	146.27%
LONG-TERM LIABILITIES
Long-Term Debt	$420.0K	$30.00K	$80.00K
YoY Change	-32.26%	-62.5%
Other Long-Term Liabilities	$40.00K	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$460.0K	$30.00K	$80.00K
YoY Change	-25.81%	-62.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.465M	$4.920M	$8.260M
Total Long-Term Liabilities	$460.0K	$30.00K	$80.00K
Total Liabilities	$5.927M	$4.951M	$8.330M
YoY Change	-26.41%	-40.56%	19.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$30.20M	-$28.58M
YoY Change
Common Stock	$2.882K	$2.818K
YoY Change	-90.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$32.00K	$32.00K
YoY Change	0.0%
Treasury Stock Shares	27.93K shares	27.93K shares	558.6K shares
Shareholders Equity	-$3.776M	-$2.881M	-$7.150M
YoY Change
Total Liabilities & Shareholders Equity	$2.151M	$2.071M	$1.190M
YoY Change	34.75%	74.0%	-4.79%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$1.624M	-$1.420M	-$1.333M
YoY Change	47.56%	6.54%	6.55%
Depreciation, Depletion And Amortization	$60.00K	$50.00K	$20.00K
YoY Change	200.0%	150.0%
Cash From Operating Activities	-$590.0K	-$810.0K	-$950.0K
YoY Change	-28.92%	-14.74%
INVESTING ACTIVITIES
Capital Expenditures	-$210.0K	-$60.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$210.0K	-$60.00K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	790.0K	730.0K	900.0K
YoY Change	-31.3%	-18.89%
NET CHANGE
Cash From Operating Activities	-590.0K	-810.0K	-950.0K
Cash From Investing Activities	-210.0K	-60.00K	0.000
Cash From Financing Activities	790.0K	730.0K	900.0K
Net Change In Cash	-10.00K	-140.0K	-50.00K
YoY Change	-103.12%	180.0%
FREE CASH FLOW
Cash From Operating Activities	-$590.0K	-$810.0K	-$950.0K
Capital Expenditures	-$210.0K	-$60.00K	$0.00
Free Cash Flow	-$380.0K	-$750.0K	-$950.0K
YoY Change	-54.22%	-21.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Assets Assets	1691801	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1746614	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1111879	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1887484	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1466506	USD
CY2015Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	56027	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	94026	USD
CY2015Q2	us-gaap	Cash Cash	6445	USD
CY2014Q4	us-gaap	Cash Cash	91798	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	2492	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1945	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34055	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20570	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	246141	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	114313	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	702348	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	493856	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1076189	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1037732	USD
CY2015Q2	us-gaap	Assets Assets	2070578	USD
CY2015Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1115319	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	5688239	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4919562	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8524999	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1539	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	5195	USD
CY2015Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	30000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	50000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	4951101	USD
CY2014Q4	us-gaap	Liabilities Liabilities	8580194	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	2818	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	1726	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25729104	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	BioRestorative Therapies, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001505497
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18541907	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28580445	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25400026	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	32000	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	32000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	-2880523	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-6888393	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2070578	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1691801	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	114118	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164349	USD
CY2015Q2	us-gaap	Security Deposit SecurityDeposit	45900	USD
CY2014Q4	us-gaap	Security Deposit SecurityDeposit	45900	USD
CY2014Q2	us-gaap	Revenues Revenues	175941	USD
CY2015Q2	us-gaap	Revenues Revenues	148764	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	42366	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	74645	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	133575	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	74119	USD
CY2014Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	15535	USD
CY2015Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	49091	USD
CY2014Q2	us-gaap	Professional Fees ProfessionalFees	557565	USD
CY2015Q2	us-gaap	Professional Fees ProfessionalFees	138991	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	293330	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	452488	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	548632	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	696353	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	1415062	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	1336923	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1281487	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1262804	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	72390	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	60096	USD
CY2014Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	145930	USD
CY2015Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	71369	USD
CY2014Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2015Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-26029	USD
CY2014Q2	brtx	Warrant Modification Expense WarrantModificationExpense	0	USD
CY2015Q2	brtx	Warrant Modification Expense WarrantModificationExpense	0	USD
CY2014Q2	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	166668	USD
CY2015Q2	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	0	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-51652	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-157494	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1333139	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-1420298	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.17
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1142606	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2227400	shares
	us-gaap	Net Income Loss NetIncomeLoss	-3002815	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	244435	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	140884	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	50139	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	89452	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1009	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	917792	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	583673	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49094	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-26029	USD
	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	176268	USD
	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-175	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	547	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2648	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13485	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-369047	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	313352	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	267810	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	641873	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1242890	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1696030	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1759925	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1484389	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	151914	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	980	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	980	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-226914	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	670000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	515000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	53000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	15015	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	274085	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	40005	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	206085	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	80000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	brtx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	945000	USD
	brtx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	1051000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1617010	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1625950	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-141935	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-85353	USD
CY2013Q4	us-gaap	Cash Cash	201098	USD
CY2014Q2	us-gaap	Cash Cash	59163	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	224975	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-50231	USD
	brtx	Payments To License Maintenance Costs PaymentsToLicenseMaintenanceCosts	75000	USD
	brtx	Payments To License Maintenance Costs PaymentsToLicenseMaintenanceCosts	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	825833	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1583769	shares
CY2015Q2	brtx	Credit Card Payable Current CreditCardPayableCurrent	3296	USD
CY2014Q4	brtx	Credit Card Payable Current CreditCardPayableCurrent	4739	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	860253	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	679277	USD
CY2015Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	43902	USD
CY2014Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	0	USD
CY2015Q2	brtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	401175	USD
CY2014Q4	brtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	292395	USD
CY2015Q2	brtx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	456077	USD
CY2014Q4	brtx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	315294	USD
CY2015Q2	brtx	Accrued Purchase Of Property And Equipment AccruedPurchaseOfPropertyAndEquipment	54781	USD
CY2014Q4	brtx	Accrued Purchase Of Property And Equipment AccruedPurchaseOfPropertyAndEquipment	174801	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2818363	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1725596	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2790431	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	BRTX
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1697664	shares
	us-gaap	Revenues Revenues	333666	USD
	us-gaap	Revenues Revenues	176316	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	151077	USD
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2826324	shares
CY2015Q2	brtx	Debt Instrument Unamortized Debt Discount Current Portion DebtInstrumentUnamortizedDebtDiscountCurrentPortion	81366	USD
CY2014Q4	brtx	Debt Instrument Unamortized Debt Discount Current Portion DebtInstrumentUnamortizedDebtDiscountCurrentPortion	113257	USD
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	27932	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	27932	shares
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	42426	USD
	us-gaap	Gross Profit GrossProfit	182589	USD
	us-gaap	Gross Profit GrossProfit	133890	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	94028	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	47329	USD
	us-gaap	Professional Fees ProfessionalFees	504060	USD
	us-gaap	Professional Fees ProfessionalFees	824763	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	859344	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	787071	USD
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1613927	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1184632	USD
	us-gaap	Operating Expenses OperatingExpenses	3071359	USD
	us-gaap	Operating Expenses OperatingExpenses	2843795	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2888770	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2709905	USD
	us-gaap	Interest Expense InterestExpense	124736	USD
	us-gaap	Interest Expense InterestExpense	145521	USD
	brtx	Warrant Modification Expense WarrantModificationExpense	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-291649	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-292910	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3180419	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.60
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.79
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1993544	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1077606	shares
	us-gaap	Accretion Expense AccretionExpense	6012	USD
	us-gaap	Accretion Expense AccretionExpense	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	50982	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Interest Paid InterestPaid	46161	USD
CY2015Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	68000	USD
	us-gaap	Interest Paid InterestPaid	43821	USD
	brtx	Conversion Of Notes Payable And Accruedinterest In To Common Stock ConversionOfNotesPayableAndAccruedinterestInToCommonStock	170065	USD
	brtx	Conversion Of Notes Payable And Accruedinterest In To Common Stock ConversionOfNotesPayableAndAccruedinterestInToCommonStock	166768	USD
	brtx	Reclassification Of Accrued Interest In Connection With Note Payable Issuance ReclassificationOfAccruedInterestInConnectionWithNotePayableIssuance	0	USD
	brtx	Reclassification Of Accrued Interest In Connection With Note Payable Issuance ReclassificationOfAccruedInterestInConnectionWithNotePayableIssuance	73058	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	10690	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	41384	USD
	brtx	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment	109487	USD
	brtx	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment	0	USD
CY2015Q2	brtx	Working Capital Net WorkingCapitalNet	4673421	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4	us-gaap	Notes Payable NotesPayable	5738239	USD
CY2015Q2	us-gaap	Notes Payable NotesPayable	1145319	USD
	brtx	Note Payable Principal Issued NotePayablePrincipalIssued	559000	USD
	brtx	Exchanges For Equity ExchangesForEquity	5020478	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	158333	USD
	brtx	Recognition Of Debt Discount RecognitionOfDebtDiscount	115005	USD
CY2015Q2	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	50982	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2015Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	152167	USD
CY2014Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8050	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	144117	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1051000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	170065	USD
	brtx	Shares Issued In Satisfaction Of Accrued Interest SharesIssuedInSatisfactionOfAccruedInterest	8481	USD
	brtx	Stocks And Warrants Issued During Period Value In Connection With Settlement Agreement StocksAndWarrantsIssuedDuringPeriodValueInConnectionWithSettlementAgreement	152000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	54415	USD
	brtx	Stocks And Warrants Issued During Period Value In Exchange Of Debt StocksAndWarrantsIssuedDuringPeriodValueInExchangeOfDebt	5142065	USD
	brtx	Warrant Modification Charge WarrantModificationCharge	15900	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	99147	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	484526	USD
	brtx	Revenue Received RevenueReceived	605359	USD
	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	491241	USD
CY2015Q1	brtx	Class Of Warrant Or Rightst Expiration Date ClassOfWarrantOrRightstExpirationDate	2015-12-31
CY2015Q2	brtx	Class Of Warrant Or Rightst Expiration Date ClassOfWarrantOrRightstExpirationDate	2017-12-31
CY2015Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	29000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	64000	USD
CY2015Q1	brtx	Class Of Warrant Or Righst Expiration Date ClassOfWarrantOrRighstExpirationDate	2015-12-31
CY2015Q2	brtx	Class Of Warrant Or Righst Expiration Date ClassOfWarrantOrRighstExpirationDate	2017-12-31
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5000	shares
CY2015Q2	brtx	Share Based Compensation Exercise Price Range Number Of Outstanding Warrants ShareBasedCompensationExercisePriceRangeNumberOfOutstandingWarrants	728850	shares
	brtx	Share Based Compensations Exercise Price Range Exercisable Warrant Weighted Average Remaining Contractual Term ShareBasedCompensationsExercisePriceRangeExercisableWarrantWeightedAverageRemainingContractualTerm	P3Y10M24D
CY2015Q2	brtx	Share Based Compensation Exercise Price Range Number Of Exercisable Warrants ShareBasedCompensationExercisePriceRangeNumberOfExercisableWarrants	693850	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	779200	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	45000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	35000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	789200	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	365327	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.18
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.49
	brtx	Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M12D
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	28500	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	317000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.82
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.34
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.25
CY2015Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	789200	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2015Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	365327	shares
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	14000	USD
CY2013Q4	us-gaap	Loss Contingency Allegations LossContingencyAllegations	The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009.
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	99147	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	240398	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	226327	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22500	USD
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	0	USD
	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	19198	shares
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	99147	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.64
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.80
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	625	shares
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4000	USD
CY2015Q2	brtx	Warrant Or Right Expense Or Revenue Recognized WarrantOrRightExpenseOrRevenueRecognized	10000	USD
	brtx	Warrant Or Right Expense Or Revenue Recognized WarrantOrRightExpenseOrRevenueRecognized	10000	USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	brtx	Indebtedness Satisfied Via Legal Settlement IndebtednessSatisfiedViaLegalSettlement	5000	USD
	brtx	Indebtedness Satisfied Via Legal Settlement IndebtednessSatisfiedViaLegalSettlement	0	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Concentrations and Credit Risk</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three and six months ended June 30, 2015. See Revenue Recognition Research and Development Agreements below.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	68000	USD
CY2014Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2014Q2	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	41384	USD
CY2015Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	315000	USD
	brtx	Warrant Modification Extension Expense WarrantModificationExtensionExpense	10000	USD
	brtx	Warrant Modification Extension Expense WarrantModificationExtensionExpense	30128	USD
	brtx	Warrants Issued During Period Number Of Warrants WarrantsIssuedDuringPeriodNumberOfWarrants	19750	shares
CY2015Q2	brtx	Warrants Issued During Period Exercise Price WarrantsIssuedDuringPeriodExercisePrice	8.75

Files In Submission

Name	View Source	Status
0001144204-15-049960-index-headers.html	Edgar Link	pending
0001144204-15-049960-index.html	Edgar Link	pending
0001144204-15-049960.txt	Edgar Link	pending
0001144204-15-049960-xbrl.zip	Edgar Link	pending
brtx-20150630.xml	Edgar Link	completed
brtx-20150630.xsd	Edgar Link	pending
brtx-20150630_cal.xml	Edgar Link	unprocessable
brtx-20150630_def.xml	Edgar Link	unprocessable
brtx-20150630_lab.xml	Edgar Link	unprocessable
brtx-20150630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v417036_10q.htm	Edgar Link	pending
v417036_ex31-1.htm	Edgar Link	pending
v417036_ex31-2.htm	Edgar Link	pending
v417036_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRTX
BioRestorative Therapies, Inc. Stock $brtx

2015 Q3 Form 10-Q Financial Statement

#000114420415049960 Filed on August 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX BioRestorative Therapies, Inc. Stock $brtx

2015 Q3 Form 10-Q Financial Statement

#000114420415049960 Filed on August 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX
BioRestorative Therapies, Inc. Stock $brtx